In this issue of JAMA, the US Preventive Services Task Force (USPSTF) presents an updated Recommendation Statement on aspirin use to prevent preeclampsia and related morbidity and mortality,1 along with an updated Evidence Report and systematic review on the use of low-dose aspirin to prevent preeclampsia, the delivery of a small for gestational age neonate, and adverse perinatal outcomes.2 The task force concluded “with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia” and “recommends the use of low-dose aspirin (81 mg/d) as preventive medication for preeclampsia after 12 weeks of gestation in persons at high risk for preeclampsia (B recommendation).”1
Espinoza J. Low-Dose Aspirin for the Prevention of Preeclampsia. JAMA. 2021;326(12):1153–1155. doi:10.1001/jama.2021.14646
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.